Literature DB >> 3300816

Allogeneic bone marrow transplantation for high risk non-Hodgkin's lymphoma during first complete remission.

A P Nademanee, S J Forman, G M Schmidt, P J Bierman, D S Snyder, M R O'Donnell, J A Lipsett, K G Blume.   

Abstract

Allogeneic bone marrow transplantation from histocompatible sibling donors was performed in six patients with extranodal involvement of high grade lymphoma during first complete remission. Five patients had lymphoblastic lymphoma and one had diffuse undifferentiated lymphoma. The cytoreductive/immunosuppressive regimen consisted of total body irradiation and high dose cyclophosphamide. Four patients are alive in complete remission at 8 months, 14 months, 21 months and 47 months post transplantation. One patient who relapsed 7 months after his initial transplantation underwent a second transplantation but another relapse 17 months later led to his death. One patient died of chronic graft-versus-host disease and at autopsy there was no evidence of lymphoma. These data demonstrate that allogeneic bone marrow transplantation can produce durable remissions in patients with high grade lymphoma who present with bone marrow, central nervous system and/or skin involvement.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3300816     DOI: 10.1007/BF00319636

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  24 in total

1.  Meaningful clinical classification of therapeutic responses to anticancer drugs.

Authors:  D A KARNOFSKY
Journal:  Clin Pharmacol Ther       Date:  1961 Nov-Dec       Impact factor: 6.875

2.  A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: methotrexate/prednisone v cyclosporine A/prednisone.

Authors:  S J Forman; K G Blume; R A Krance; P J Miner; G E Metter; L R Hill; M R O'Donnell; A P Nademanee; D S Snyder
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

3.  An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults.

Authors:  I T Magrath; C Janus; B K Edwards; R Spiegel; E S Jaffe; C W Berard; J Miliauskas; K Morris; R Barnwell
Journal:  Blood       Date:  1984-05       Impact factor: 22.113

4.  MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma.

Authors:  P Klimo; J M Connors
Journal:  Ann Intern Med       Date:  1985-05       Impact factor: 25.391

5.  Improved results of treatment of adult acute lymphoblastic leukemia.

Authors:  C A Linker; L J Levitt; M O'Donnell; C A Ries; M P Link; S J Forman; M J Farbstein
Journal:  Blood       Date:  1987-04       Impact factor: 22.113

6.  High-dose chemotherapy, fractionated total-body irradiation, and allogeneic marrow transplantation for malignant lymphoma.

Authors:  G L Phillips; R H Herzig; H M Lazarus; J W Fay; R Griffith; G P Herzig
Journal:  J Clin Oncol       Date:  1986-04       Impact factor: 44.544

Review 7.  Karnofsky Memorial Lecture. Marrow transplantation for malignant diseases.

Authors:  E D Thomas
Journal:  J Clin Oncol       Date:  1983-09       Impact factor: 44.544

8.  Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.

Authors:  R I Fisher; V T DeVita; S M Hubbard; D L Longo; R Wesley; B A Chabner; R C Young
Journal:  Ann Intern Med       Date:  1983-03       Impact factor: 25.391

9.  Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD).

Authors:  A T Skarin; G P Canellos; D S Rosenthal; D C Case; J M MacIntyre; G S Pinkus; W C Moloney; E Frei
Journal:  J Clin Oncol       Date:  1983-02       Impact factor: 44.544

10.  Bone marrow transplantation for non-Hodgkin's lymphoma in children and young adults. A pilot study.

Authors:  M O'Leary; N K Ramsay; M E Nesbit; D Hurd; W G Woods; W Krivit; T H Kim; P McGlave; J Kersey
Journal:  Am J Med       Date:  1983-03       Impact factor: 4.965

View more
  2 in total

1.  Fractionated total body irradiation and high dose cyclophosphamide: a preparative regimen for bone marrow transplantation for patients with hematologic malignancies in first complete remission.

Authors:  D S Snyder; D O Findley; S J Forman; A P Nademanee; M R O'Donnell; G M Schmidt; P J Bierman; J L Fahey; R A Krance; I J Sniecinski
Journal:  Blut       Date:  1988-07

2.  Treatment of recurrent metastatic medulloblastoma with intensive chemotherapy and allogeneic bone marrow transplantation.

Authors:  J H Lundberg; D E Weissman; P A Beatty; R C Ash
Journal:  J Neurooncol       Date:  1992-06       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.